Payment overview · 2025
General Payments
$348.97
4 reported records · 4 companies
Healthcare provider profile · identity verified
Sayed Elsayyad, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROCKVILLE, MD · NPI 1093764953
Verified facts
What the public records show
CMS Open Payments records show Sayed Elsayyad, M.D. received $348.97 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $122.09 | 35.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $121.87 | 34.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $89.82 | 25.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.19 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $348.97 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $122.09 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $89.82 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 365 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 67 |
| Gabapentin | Gabapentin | 243 | 59 |
| Eliquis | Apixaban | 233 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 38 |
| Trazodone Hcl | Trazodone Hcl | 157 | 32 |
| Losartan Potassium | Losartan Potassium | 141 | 52 |
| Furosemide | Furosemide | 125 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 22 |
| Enulose | Lactulose | 115 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 35 |
| Carvedilol | Carvedilol | 108 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 36 |
| Lisinopril | Lisinopril | 105 | 28 |
| Donepezil Hcl | Donepezil Hcl | 102 | 18 |
| Levetiracetam | Levetiracetam | 101 | 16 |
| Omeprazole | Omeprazole | 100 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 23 |
| Famotidine | Famotidine | 80 | 26 |
| Potassium Chloride | Potassium Chloride | 75 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 20 |
| Mirtazapine | Mirtazapine | 69 | 26 |
| Xarelto | Rivaroxaban | 66 | suppressed |
| Latanoprost | Latanoprost | 59 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 57 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 50 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 49 | suppressed |
| Acetazolamide Er | Acetazolamide | 47 | suppressed |
| Metformin Hcl | Metformin Hcl | 47 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Allopurinol | Allopurinol | 33 | 12 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 20 |
| Risperidone | Risperidone | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | 11 |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Rytary | Carbidopa/Levodopa | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $348.97 · 4 records | AstraZeneca Pharmaceuticals LP | FREESTYLE LIBRE 3, REXULTI, TEZSPIRE, Yeztugo | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error